These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18157598)

  • 61. Erlotinib for the treatment of non-small-cell lung cancer.
    Boysen M; Longson C; Stevens A
    Lancet Oncol; 2009 Jan; 10(1):15-6. PubMed ID: 19115513
    [No Abstract]   [Full Text] [Related]  

  • 62. The use of erlotinib in daily practice: a study on adherence and patients' experiences.
    Timmers L; Boons CC; Mangnus D; Moes JE; Swart EL; Boven E; Smit EF; Hugtenburg JG
    BMC Cancer; 2011 Jul; 11():284. PubMed ID: 21722354
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Second-line erlotinib for non-small-cell lung cancer.
    Lorusso V; Cinieri S
    Lancet Oncol; 2012 Apr; 13(4):e141-2; author reply e142. PubMed ID: 22469123
    [No Abstract]   [Full Text] [Related]  

  • 64. Gefitinib for refractory advanced non-small-cell lung cancer.
    Tsurutani J; Ballas M; Steinberg SM; Egilsson V; Dennis PA
    Lancet; 2006 Jan; 367(9507):300. PubMed ID: 16443034
    [No Abstract]   [Full Text] [Related]  

  • 65. [Adverse effects of new biological therapies for non-small-cell bronchial cancer].
    Castel M; Pathak A; Despas F; Mazières J
    Presse Med; 2011 Apr; 40(4 Pt 1):415-9. PubMed ID: 21392933
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv158-iv161. PubMed ID: 28881928
    [No Abstract]   [Full Text] [Related]  

  • 67. Key questions for perioperative chemotherapy in resectable lung cancer: not pre vs post, but who and what?
    Wakelee HA; Merritt R; Clément-Duchêne C
    Oncology (Williston Park); 2009 May; 23(6):527, 532. PubMed ID: 19544694
    [No Abstract]   [Full Text] [Related]  

  • 68. Onartuzumab ineffective in non-small-cell lung cancer.
    Brower V
    Lancet Oncol; 2017 Feb; 18(2):e66. PubMed ID: 28017663
    [No Abstract]   [Full Text] [Related]  

  • 69. Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma.
    Bleehen NM; Ball D; Belani CP; Bishop J; Douillard JY; Cox JD; Johnson DH; Le Chevalier T; Saunders MI; Shaw E
    Lung Cancer; 1994 Mar; 10 Suppl 1():S19-23. PubMed ID: 8087510
    [No Abstract]   [Full Text] [Related]  

  • 70. VeriStrat validated in patients with non-small-cell lung cancer.
    Butts CA
    Lancet Oncol; 2014 Jun; 15(7):671-2. PubMed ID: 24831978
    [No Abstract]   [Full Text] [Related]  

  • 71. KRAS wild-type lung cancer: a moving target in an era of genotype migration.
    Oxnard GR; Jänne PA
    J Clin Oncol; 2012 Sep; 30(27):3322-4. PubMed ID: 22869875
    [No Abstract]   [Full Text] [Related]  

  • 72. Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC.
    Mehta P; Hamid O; Klempner SJ
    J Thorac Oncol; 2017 Dec; 12(12):1857-1858. PubMed ID: 28774860
    [No Abstract]   [Full Text] [Related]  

  • 73. Are we expanding oligometastatic non-small-cell lung cancer using advanced radiotherapeutic modalities?
    Jabbour SK
    J Clin Oncol; 2014 Dec; 32(34):3794-6. PubMed ID: 25349298
    [No Abstract]   [Full Text] [Related]  

  • 74. Monitoring cancer through the blood.
    Paweletz CP; Jänne PA
    Cancer; 2014 Dec; 120(24):3859-61. PubMed ID: 25103496
    [No Abstract]   [Full Text] [Related]  

  • 75. Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer.
    Belani CP
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S6. PubMed ID: 15638958
    [No Abstract]   [Full Text] [Related]  

  • 76. Updated data from the Iressa survival in lung cancer trial.
    Tyagi P
    Clin Lung Cancer; 2005 May; 6(6):340-2. PubMed ID: 15943893
    [No Abstract]   [Full Text] [Related]  

  • 77. KL-6 and poor prognosis in NSCLC patients treated with gefitinib.
    Ohara G; Kurishima K; Ishikawa H; Satoh H; Hizawa N
    Lung Cancer; 2008 Jan; 59(1):138; author reply 139. PubMed ID: 18006181
    [No Abstract]   [Full Text] [Related]  

  • 78. Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?
    Todd A; Williamson S; Husband A; Baqir W; Mahony M
    Int J Clin Pharm; 2013 Apr; 35(2):181-4. PubMed ID: 23229875
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Not Available].
    López-Brea M
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():1. PubMed ID: 27426240
    [No Abstract]   [Full Text] [Related]  

  • 80. 3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world.
    Lin CC; Hsia TC; Chien CR
    Lung Cancer; 2012 Jun; 76(3):499-500. PubMed ID: 22503286
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.